价格:面议
生产地:品牌:MedChemExpress (MCE)
移动电话:18019480960公司传真:86-021-53700325
更新时间:2019-06-28
MedChemExpress (MCE) 专注于为全球科学家提供高品质的生物活性小分子化合物,化合物库及各类试剂盒,总部位于美国新泽西。
MedChemExpress (MCE) 产品作用于 20 多个热门信号通路及研究领域的300多个细分靶点,拥有 10000 特异性抑制剂、激动剂,以及 30 活性化合物筛选库;
我们坚持对所有产品进行严格质检,确保产品的高品质和高纯度;
MedChemExpress (MCE) 产品已被全球数万名科学家信赖,并被大量Top文献和Patent引用;
我们拥有专业的技术团队追踪全球前沿科技进展,不断丰富各个靶点的特异性产品,坚持做 您身边的抑制剂大师 ;
MedChemExpress (MCE) 与全球众多知名药企和科研机构保持深度合作;
大量产品有中国库存,工作日 16:00 前订单确保当日发货,次日送达。
MCE 中国:www.MedChemExpress.cn
Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656
Darapladib
产品活性:Darapladib 是一种有效的脂蛋白相关磷脂酶A2 (Lp-PLA2) 抑制剂,IC50 为 0.25 nM。
研究领域:metabolic Enzyme/Protease
作用靶点:Phospholipase
In Vitro: Mechanistic studies using steady state and transient kinetics indicate Darapladib (SB-480848) to be a freely reversible, non-covalently bound, inhibitor of rhLp-PLA2 with a Ki of 110 pM and an off-rate of 27 min. Potent inhibition of the enzyme in whole human plasma is confirmed (IC50=5 2 nM). Furthermore, the presence of Darapladib during the copper catalysed oxidation of human LDL prevents the production of lyso-PtdCho (IC50=4 3 nM) and subsequent monocyte chemotaxis (IC50=4 1 nM).
In Vivo: Additional in vivo studies with Darapladib indicated an oral bioavailability of 11 2% in the fed rat. The oral bioavailability of Darapladib is 28 4% in the dog. Furthermore excellent inhibition of Lp-PLA2 within the atherosclerotic plaque is achieved for Darapladib, with 95 1% inhibition observed 2 h after an oral dose of 30 mg/kg to the WHHL rabbit. Darapladib, a specific inhibitor of lipoprotein-associated phospholipase A2 (lp-PLA2), on inflammation and atherosclerotic formation in the low density lipoprotein receptor (LDLR)-deficient mice. the activity of serum lp-PLA2 is inhibited by more than 60% in LDLR-deficient mice after oral administration of 50 mg/kg once daily of Darapladib for 6 weeks. Darapladib significantly inhibits serum lp-PLA2 activity in LDLR-deficient mice.
相关产品:Drug Repurposing Compound Library | Clinical Compound Library | Clinical Compound Library Plus | metabolism/Protease Compound Library | Drug Repurposing Compound Library Plus | Bioactive Compound Library Plus | U-73122 | D609 | Quinacrine dihydrochloride | FIPI | Melittin | ML348 | Varespladib | Tanshinone I | AA26-9 | Levobupivacaine hydrochloride | CAY10650 | ML349 | N-(p-amylcinnamoyl) Anthranilic Acid | ST271 | 1-Linoleoyl Glycerol | MAFP | Lp-PLA2 -IN-1 | SPK-601 | DB550 | Ecopladib | LY 178002 | 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide | 3-Nitrocoumarin | D-Erythro-dihydrosphingosine | sPLA2-X Inhibitor 31 | U-73343